Appili Therapeutics (OTCMKTS:APLIF – Get Free Report) issued its quarterly earnings results on Friday. The company reported ($0.01) EPS for the quarter, Zacks reports. The firm had revenue of $0.03 million for the quarter.
Appili Therapeutics Stock Up 5.9%
OTCMKTS APLIF traded up $0.00 during trading hours on Thursday, hitting $0.01. The company had a trading volume of 55,000 shares, compared to its average volume of 15,622. The business has a fifty day simple moving average of $0.01 and a 200-day simple moving average of $0.01. The firm has a market cap of $1.42 million, a P/E ratio of -0.27 and a beta of -0.03. Appili Therapeutics has a fifty-two week low of $0.01 and a fifty-two week high of $0.03.
Appili Therapeutics Company Profile
Appili Therapeutics Inc is a clinical-stage pharmaceutical company headquartered in Vancouver, Canada. The company specializes in the development and commercialization of novel anti-infective therapies designed to address both endemic and emerging infectious disease threats. Appili’s strategic focus includes small-molecule antibiotics, antivirals and vaccine adjuvants, with an emphasis on formulations suitable for rapid deployment in resource-limited or outbreak settings.
Appili’s product pipeline features multiple candidates in various stages of development.
Further Reading
- Five stocks we like better than Appili Therapeutics
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Receive News & Ratings for Appili Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Appili Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
